Difference between revisions of "Part:BBa K200028"
Line 2: Line 2:
 
<partinfo>BBa_K200028 short</partinfo>
 
<partinfo>BBa_K200028 short</partinfo>
  
−
The Homo <i>sapiens</i> endogenous enzyme is synthesised by the liver. However, as part of the Imperial College iGEM 2009 project, [http://2009.igem.org/Team:Imperial_College_London <i>The E.ncapsulator</i>], the enzyme is released in the intestine of the individual. The presence of proteases in the intestine was therefore a serious problem which would jeopardise the viability of the curative enzyme.
+
The Homo <i>sapiens</i> endogenous enzyme is synthesised by the liver.  
−
We therefore performed site directed mutagenesis in order to alter a serine residue (Ser16) to a glutamine as this change has previously been correlated with resistance against intestinal proteases . This will allow safe passage through the stomach and gut in order to carry out function as required by Imperial College's 2009 iGEM project, [http://2009.igem.org/Team:Imperial_College_London <i>The E.ncapsulator</i>].
+
However, as part of the Imperial College iGEM 2009 project, [http://2009.igem.org/Team:Imperial_College_London <i>The E.ncapsulator</i>], the enzyme is released in the intestine of the individual. The presence of proteases in the intestine was therefore a serious problem which would jeopardise the viability of the curative enzyme.
 +
We thus performed site directed mutagenesis in order to alter a serine residue (Ser16) to a glutamine. This change has previously been correlated with resistance against intestinal proteases<cite>#PRPAH1</cite>.
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
Line 20: Line 21:
  
 
<biblio>
 
<biblio>
−
 
+
#PRPAH1 pmid=7887915
 
</biblio>
 
</biblio>

Revision as of 23:19, 18 October 2009

Protease resistant PAH

The Homo sapiens endogenous enzyme is synthesised by the liver. However, as part of the Imperial College iGEM 2009 project, [http://2009.igem.org/Team:Imperial_College_London The E.ncapsulator], the enzyme is released in the intestine of the individual. The presence of proteases in the intestine was therefore a serious problem which would jeopardise the viability of the curative enzyme. We thus performed site directed mutagenesis in order to alter a serine residue (Ser16) to a glutamine. This change has previously been correlated with resistance against intestinal proteases#PRPAH1.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 287
    Illegal BamHI site found at 814
    Illegal XhoI site found at 524
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


<biblio>

  1. PRPAH1 pmid=7887915

</biblio>